2011
DOI: 10.2147/jpr.s23024
|View full text |Cite
|
Sign up to set email alerts
|

Effectiveness and safety of morphine sulfate extended-release capsules in patients with chronic, moderate-to-severe pain in a primary care setting

Abstract: BackgroundThe purpose of this study was to determine the effectiveness and safety of morphine sulfate extended-release capsules among primary care patients with chronic, moderate-to-severe pain using a universal precautions approach that assessed and monitored risk for opioid misuse and abuse.MethodsThis open-label, uncontrolled, multicenter, prospective study was conducted in primary care centers (n = 281) and included opioid-naïve and opioid-experienced patients with either a pain score ≥4 (0 = no pain, 10 =… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

3
1
0

Year Published

2012
2012
2022
2022

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 25 publications
3
1
0
Order By: Relevance
“… 12 , 18 20 Gastrointestinal side effects such as constipation and nausea observed in the present study are consistent with those previously described for MSN 12 , 18 20 and those commonly observed during ER morphine sulfate therapy. 38 Specifically, the rate of TEAEs resulting in discontinuation in the present study (22.4%) was consistent with that described by Katz et al 18 (n=130/547; 23.8%) and Webster et al (n=46/197; 23.3%). 12 Brown et al evaluated ER morphine sulfate in both opioid-naïve and opioid-experienced patients in a primary care setting and found TEAEs resulting in discontinuation to be 21%.…”
Section: Discussionsupporting
confidence: 91%
See 2 more Smart Citations
“… 12 , 18 20 Gastrointestinal side effects such as constipation and nausea observed in the present study are consistent with those previously described for MSN 12 , 18 20 and those commonly observed during ER morphine sulfate therapy. 38 Specifically, the rate of TEAEs resulting in discontinuation in the present study (22.4%) was consistent with that described by Katz et al 18 (n=130/547; 23.8%) and Webster et al (n=46/197; 23.3%). 12 Brown et al evaluated ER morphine sulfate in both opioid-naïve and opioid-experienced patients in a primary care setting and found TEAEs resulting in discontinuation to be 21%.…”
Section: Discussionsupporting
confidence: 91%
“… 37 This supports existing data reporting the analgesic efficacy of MSN for chronic moderate-to-severe pain 12 , 18 20 and data reporting analgesic efficacy of ER morphine sulfate formulations. 38 Pain scores remained elevated in patients who did not achieve a stable dose, and the magnitude of pain relief experienced by the majority of those who achieved a stable dose was consistent with that previously reported. 12 This suggests that inadequate pain control may be a risk factor for not achieving conversion.…”
Section: Discussionsupporting
confidence: 87%
See 1 more Smart Citation
“…Although non-steroidal anti-inflammatory drugs are the first line of defense against LBP, they do not sufficiently treat chronic and severe LBP. Opioids are often prescribed with varying therapeutic outcome [ 1 , 14 , 15 ] and are associated with undesired effects that limit their use, such as constipation, nausea, somnolence, fatigue, and the development of tolerance [ 16 ]. Since opioids such as morphine remain the gold standard of chronic pain treatment, it is vital to investigate strategies that would decrease required doses without diminishing the therapeutic effects.…”
Section: Introductionmentioning
confidence: 99%